Abstract
Critical limb ischemia (CLI) is a terminal stage of peripheral artery disease (PAD). The number of patients with CLI is increasing, and the disease has a major impact on patients quality of life. In spite of the marked advances in surgery and interventional angioplasty, a large number of patients require revascularization. To treat these patients, cell based angiogenesis is attracting a great deal of attention as a new strategy. “Therapeutic angiogenesis” is a term that has become widely used in the last decade. Despite negative results in several clinical trials of cytokine-based angiogenesis, cell based therapy produced effective angiogenesis. This cell-based angiogenesis originates from persistent basic research. The first clinical randomized pilot study was reported in 2002. Up to now, more than 30 clinical studies on the use of mononuclear cells or progenitor cells for the treatment have been published. As the prognosis of the patients with CLI is poor, it has been discussed with respect to their safety and feasibility. With the increasing number of treated patients, the accumulated outcomes from these clinical studies are demonstrating this therapy to be reliable. They reveal indications of the stage of the patients with PAD and the timing of treatments. However, clinical data concerning long time prognosis and a standardized protocol have not been discussed sufficiently. This review summarises data from recent clinical outcomes from 17 studies (11 involving BMMNC that included > 10 patients, 6 involving PBMNC that included > 10 patients) that are treating patients with PAD by autologous cell transplantation.
Keywords: Peripheral artery disease, therapeutic angiogenesis, bone marrow mononuclear cell, peripheral blood-derived mononuclear cells, endothelial progenitor cell
Current Pharmaceutical Design
Title: Therapeutic Angiogenesis for Peripheral Artery Diseases by Autologous Bone Marrow Cell Transplantation
Volume: 15 Issue: 24
Author(s): Satoaki Matoba and Hiroaki Matsubara
Affiliation:
Keywords: Peripheral artery disease, therapeutic angiogenesis, bone marrow mononuclear cell, peripheral blood-derived mononuclear cells, endothelial progenitor cell
Abstract: Critical limb ischemia (CLI) is a terminal stage of peripheral artery disease (PAD). The number of patients with CLI is increasing, and the disease has a major impact on patients quality of life. In spite of the marked advances in surgery and interventional angioplasty, a large number of patients require revascularization. To treat these patients, cell based angiogenesis is attracting a great deal of attention as a new strategy. “Therapeutic angiogenesis” is a term that has become widely used in the last decade. Despite negative results in several clinical trials of cytokine-based angiogenesis, cell based therapy produced effective angiogenesis. This cell-based angiogenesis originates from persistent basic research. The first clinical randomized pilot study was reported in 2002. Up to now, more than 30 clinical studies on the use of mononuclear cells or progenitor cells for the treatment have been published. As the prognosis of the patients with CLI is poor, it has been discussed with respect to their safety and feasibility. With the increasing number of treated patients, the accumulated outcomes from these clinical studies are demonstrating this therapy to be reliable. They reveal indications of the stage of the patients with PAD and the timing of treatments. However, clinical data concerning long time prognosis and a standardized protocol have not been discussed sufficiently. This review summarises data from recent clinical outcomes from 17 studies (11 involving BMMNC that included > 10 patients, 6 involving PBMNC that included > 10 patients) that are treating patients with PAD by autologous cell transplantation.
Export Options
About this article
Cite this article as:
Matoba Satoaki and Matsubara Hiroaki, Therapeutic Angiogenesis for Peripheral Artery Diseases by Autologous Bone Marrow Cell Transplantation, Current Pharmaceutical Design 2009; 15 (24) . https://dx.doi.org/10.2174/138161209788923840
DOI https://dx.doi.org/10.2174/138161209788923840 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index to Volume 2
Current Vascular Pharmacology Platelet Hyperreactivity and Stent Thrombosis in Patients Undergoing Coronary Stenting
Current Vascular Pharmacology Analysis of Homocysteine in Plasma of Rats Exposed to High-fat Diet and Chronic Unpredictable Mild Stress by LC/ESI-MS/MS
Current Analytical Chemistry Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement: Meta-Analysis of Clinical Outcomes and Cost-Effectiveness
Current Pharmaceutical Design By Discontinuing Beta-Blockers Before an Exercise Test, We may Precipitate a Rebound Phenomenon
Current Vascular Pharmacology Etiology of the Metabolic Syndrome
Current Cardiology Reviews Alternative Pharmacological Interventions that Limit Myocardial Infarction
Current Medicinal Chemistry Green Tea Catechins and Cardiovascular Health: An Update
Current Medicinal Chemistry Hypotensive Effects of the Triterpene Oleanolic Acid for Cardiovascular Prevention
Current Molecular Pharmacology Cerebral Aneurysm Formation in Nitric Oxide Synthase-3 Knockout Mice
Current Neurovascular Research Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism Use of Clinically Available PPAR Agonists for Heart Failure; Do the Risks Outweigh the Potential Benefits?
Current Molecular Pharmacology Interventions to Prevent Long-Term Consequences of Bronchiolitis
Current Respiratory Medicine Reviews Targeting Antibody-Mediated Rejection in the Setting of ABOIncompatible Infant Heart Transplantation: Graft Accommodation vs. B Cell Tolerance
Current Drug Targets - Cardiovascular & Hematological Disorders Artificial Intelligence Approaches for Rational Drug Design and Discovery
Current Pharmaceutical Design Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill Patients
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Different Omega-3 Formulations Yield to Diverse Clinical Response: A Case-Report
Current Drug Safety How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with Type 2 Diabetes?
Vascular Disease Prevention (Discontinued) Cardiac Regeneration by Progenitor Cells: What Is It Known as and What Is It Still to Be Known as?
Cardiovascular & Hematological Agents in Medicinal Chemistry Effects of Bisphosphonates and Calcium plus Vitamin-D Supplements on Cognitive Function in Postmenopausal Osteoporosis§
Endocrine, Metabolic & Immune Disorders - Drug Targets